Redx Pharma Quits London Stock Exchange's AIM

By
Marcello Serrano
1 min read

Biotech company Redx Pharma Plc has announced its decision to pull its shares from the London Stock Exchange's smallest market, citing liquidity constraints and expressing its belief that it will be more appealing to investors as a private entity. This move is indicative of a broader trend where innovative biotech companies are increasingly choosing to sell shares in New York or relocate their listings there, as evidenced by companies such as Barinthus Biotherapeutics, Zura Bio, and OKYO Pharma. The shift raises questions about the attractiveness and potential benefits of the US markets compared to their counterparts in London.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines.The cover photo is computer generated art for illustrative purposes only; not indicative of factual content.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings